<SEC-DOCUMENT>0001178913-15-001742.txt : 20150520
<SEC-HEADER>0001178913-15-001742.hdr.sgml : 20150520
<ACCEPTANCE-DATETIME>20150520085711
ACCESSION NUMBER:		0001178913-15-001742
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150520
FILED AS OF DATE:		20150520
DATE AS OF CHANGE:		20150520

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAMADA LTD
		CENTRAL INDEX KEY:			0001567529
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35948
		FILM NUMBER:		15878338

	BUSINESS ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
		BUSINESS PHONE:		97289406472

	MAIL ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1516818.htm
<DESCRIPTION>6-K
<TEXT>
<html>
<head>
    <title>zk1516818.htm</title>
    <!--Licensed to: zkg-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">FORM 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule 13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the Month of May, 2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 001-35948</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Kamada Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7 Sapir St.</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Kiryat Weizmann Science Park</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">P.O Box 4081</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ness Ziona 74140</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Israel</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form 20-F <font style="DISPLAY: inline;" face="Wingdings 2, serif">T<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font>Form 40-F <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="DISPLAY: inline;" face="Wingdings">&#168;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font>No <font style="DISPLAY: inline;" face="Wingdings 2, serif">T</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">This Form 6-K is being incorporated by reference into the Registrant&#8217;s Form S-8 Registration Statement File No. 333-192720.</font></div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following exhibit is attached:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;News Release: Kamada Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -9pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -9pt" align="left">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May 20, 2015</font></font></div>
</td>
<td colspan="2" valign="top" width="24%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font></font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">KAMADA LTD.</font></font></font></div>
</td>
<td valign="top" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="21%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gil Efron</font></font></td>
<td valign="top" width="26%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="24%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gil Efron</font></font></div>
</td>
<td valign="top" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="24%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></font></div>
</td>
<td valign="top" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -9pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT INDEX</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">EXHIBIT NO.</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="92%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">DESCRIPTION</font></font></div>
</td>
</tr><tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="92%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="8%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">News Release: Kamada Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>exhibit_99-1.htm</title>
    <!--Licensed to: zkg-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold; TEXT-DECORATION: underline">EXHIBIT 99.1</font></div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="FONT-FAMILY: times new roman; FONT-SIZE: 18pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">News Release</font></font></font></td>
<td width="50%" style="TEXT-ALIGN: right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<img src="logo.jpg" alt=""></font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Kamada Reports Updated Data from European Phase 2/3 Clinical Study</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">&#160;of</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">&#160;Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency</font></div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Additional analyses demonstrate that inhaled AAT is able to change the nature of </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">exacerbations to events with fewer symptoms (statistically significant), a change that</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;correlates with the benefit seen in lung function.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Data highlighted in panel discussion with renowned pulmonology experts who specialize</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;in treating patients with alpha-1 antitrypsin deficiency will serve as basis for MAA </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">submission in Europe</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NESS ZIONA, Israel (May 20, 2015) &#8211; Kamada Ltd. (NASDAQ and TASE: KMDA), </font>a plasma-derived protein therapeutics company focused on orphan indications, reports the discussion of the updated data from the Company&#8217;s European and Canadian Phase 2/3 clinical study of inhaled alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) during a panel discussion entitled, &#8220;New Treatment Prospects for AATD Patients: Results from a Phase 2/3 Inhaled AAT Trial,&#8221; which was chaired by Robert A. Sandhaus, Ph.D., M.D., FCCP, Founder and Director of the Alpha1- Antitrypsin Deficiency Program at National Jewish Health Hospital in Denver, Colorado, and the Clinical Director of the Alpha-1 Foundation.&#160;&#160;The panel included Key Opinion Leaders (KOLs) who specialize in treating patients with AATD, and was held during the American Thoracic Society (ATS) 2015 International Conference held from May 15-20, 2015 in Denver, Colorado.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The slides from the presentation are now available and a video of the panel discussion in its entirety will be available on the homepage of the Company&#8217;s website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.kamada.com</font> beginning May 25, 2015.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to previously announced results that focused on the statistically significant lung function beneficial effect, additional data on the nature of symptoms of the first exacerbation, a clinically important measurement, were reported during the panel session.&#160;&#160;In the study, three major exacerbation symptoms comprised the severity nature of an exacerbation:&#160;&#160;dyspnea, sputum volume and sputum color.&#160;&#160;These symptoms were scored by patients using a daily electronic diary device.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The inhaled AAT treated group showed a statistically significant lower symptoms score (for both dyspnea and volume) for patients who&#160;experienced first exacerbation versus the placebo group for events:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 20.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">0-10 days for dyspnea the AAT group scored 11.94 vs 12.25 for placebo, p=0.0243</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 20.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">0-14 days for dyspnea the AAT group scored 11.58 vs 11.78 for placebo, p=0.0817</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 20.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">0-10 for sputum volume<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>the AAT group scored<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>1.27 vs 1.38 for placebo, p=0.0334<font style="DISPLAY: inline; FONT-WEIGHT: bold">,</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 20.5pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">0-14 days for sputum volume the AAT group scored 1.23 vs 1.32 for placebo, p=0.0595</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, the inhaled AAT group had a lower percentage of patients who experienced all 3 symptoms during the first exacerbation (type I exacerbation) of the first exacerbation&#160;versus the placebo group (18.8% vs. 31.3%, p=0.06).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Key highlights of the updated data set include:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8226;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Statistically significant lung function efficacy</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8226;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Change in the nature of exacerbations (reduction in number of Type 1- exacerbations (trend) and reduction in dyspnea score (statistically significant)</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8226;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The trial did not achieve statistical significance in primary endpoint of time to first exacerbation</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8226;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The drug is safe and tolerable</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Key comments by the KOLs who participated in the panel discussion:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;The lung function results seen in this study are striking and the change is quite rapid.&#160;&#160;This is the first time a controlled randomized study in AATD has demonstrated actual efficacy in lung function, the gold standard endpoint in respiratory trials, &#8220; said Kenneth R. Chapman, M.D., Director, Canadian Registry Alpha-1 Antitrypsin Deficiency, Asthma and Airway Centre, Toronto Western Hospital, University of Toronto, Toronto, Canada.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;These results reinforce the known anti-inflammatory effects of AAT on neutrophil migration and elastase release, and thereby, on inflammation in the lung.&#160;&#160;This is a very important finding as it could be applicable in a number of respiratory conditions where lung inflammation exists,&#8221; explained Gerry McElvaney, M.D., Professor of Medicine at Royal College of Surgeons in Ireland (RCSI), Dublin Ireland.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;The change in lung function would support the use of this treatment in our AATD patient population and I would be most interested in seeing the long-term benefits of this therapy in these patients,&#8221; stated Jan Stolk, M.D., Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;The study has shown that inhaled AAT has the capacity of changing the nature of exacerbation events. The results indicated&#160;that the treatment lead to exacerbations with fewer symptoms. This change was associated with a benefit in lung function which may explain the effect,&#8220; noted Robert A. Stockley, M.D., Lung Investigation Unit, Queen Elizabeth Hospital, Birmingham University, Birmingham, United Kingdom.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We are especially pleased to report updated results from our European Phase 2/3 clinical study, which showed clinically and statistically significant improvements in spirometric measures of lung function and complementary efficacy in the severity of the first exacerbation.&#160;&#160;These data are particularly exciting as they demonstrate clinical primacy in efficacy for inhaled AAT specifically and in AATD in general,&#8221; stated David Tsur, co-founder and Chief Executive Officer of Kamada.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We continue with our plans to submit a Marketing Authorization Application with the European Medicines Agency for approval of our inhaled AAT by year-end 2015 and are confident that the totality of this data set will support our efforts to bring inhaled AAT to the market place in order to provide an adequate, efficacious, safe and easy-to-use answer to the current unmet medical need of these orphan patients.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We remain committed to the AATD patient community and appreciate the ongoing support for and recognition of these positive data from the leading clinicians in the field and from patient advocacy groups worldwide,&#8221; concluded Mr. Tsur.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Kamada</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline.&#160;&#160;The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins.&#160;AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company&#8217;s flagship product is Glassia&#174;, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International.&#160;&#160;In addition to Glassia, Kamada has a product line of nine other injectable pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia.&#160;&#160;Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed pivotal Phase 2/3 clinical trials in Europe and entered Phase 2 clinical trials in the U.S.&#160;Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cautionary Note Regarding Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.&#160;&#160;Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations.&#160;&#160;Forward-looking statements are based on Kamada&#8217;s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions.&#160;&#160;Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays.&#160;&#160;The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contacts:</font></font></div>
</td>
<td width="14%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="53%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anne Marie Fields</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gil Efron&#160;</font></td>
<td width="14%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="53%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">LHA</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CFO&#160;&#160;&#160;</font></td>
<td width="14%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="53%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">212-838-3777</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">ir@kamada.com</font>&#160;&#160;&#160;&#160;&#160;</font></td>
<td width="14%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="53%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">afields@lhai.com</font></font></td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><br>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`$D!
M`@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W?UG6;FTU*6..7:BXP-H/8>U5?^$AO/^>W_CB_X4>(?^0Q-_P'
M_P!!%4J`+O\`PD-Y_P`]O_'%_P`*/^$AO/\`GM_XXO\`A5*O!?VE/^"AO@/]
MG:>33FNAKVOJ/^/"R8,8CZ.W13[&NO!8#$8NJJ.&@Y2?1?KV^9QX[,,-@Z3K
M8J:A%=7^G?Y'T/\`\)#>?\]O_'%_PH_X2&\_Y[?^.+_A7YWVW_!0_P",/QSO
MKA/!7A\P0VY&X6-L+B2,'INSQGZ5IZ%^TE\?+G3);Z<:JUG;%A-,=.C")M.&
M!..,$<U]0^!\=%?O:E.+[.6OX)GQD_$;+KWI4JLX]U#1VWM=K8^_?^$AO/\`
MGM_XXO\`A1_PD-Y_SV_\<7_"OB[P1_P4,\0:5,J:YIUMJ4'&YX_W<O\`A7TC
M\(_CUX=^,VGB72KM5NE&9+67Y98_P[CW%>1F7#N.P*YZT/=[K5?\#YGLY-Q?
ME>9R]GAZEI_RRT?RZ/Y-GH'_``D-Y_SV_P#'%_PH_P"$AO/^>W_CB_X52H)`
MZD#ZUX9],7?^$AO/^>W_`(XO^%'_``D-Y_SV_P#'%_PJEN'JOYTH!)P!DT`7
M/^$AO/\`GM_XXO\`A1_PD-Y_SV_\<7_"J9!!P>#Z=Z0G')P`*`+O_"0WG_/;
M_P`<7_"C_A(;S_GM_P".+_A5%)%E7<CHZ^JD$?I2YH"Y=_X2&\_Y[?\`CB_X
M4?\`"0WG_/;_`,<7_"J60>A!_&B@"[_PD-Y_SV_\<7_"C_A(;S_GM_XXO^%4
MJ,@=2!^-`%W_`(2&\_Y[?^.+_A1_PD-Y_P`]O_'%_P`*I4DDJ1+N=T1>F6(`
M_6@+E[_A(;S_`)[?^.+_`(4?\)#>?\]O_'%_PJEF@D#J0,^IQ0!=_P"$AO/^
M>W_CB_X4?\)#>?\`/;_QQ?\`"J0()P""3[TI4KU!%%P+G_"0WG_/;_QQ?\*/
M^$AO/^>W_CB_X52HH`N_\)#>?\]O_'%_PH_X2&\_Y[?^.+_A5$2HSLH="Z]5
M#`E?J.U+0%R[_P`)#>?\]O\`QQ?\*/\`A(;S_GM_XXO^%4J*`.THHHH`YCQ#
M_P`AB;_@/_H(JE5WQ#_R&)O^`_\`H(KA?CQ\4;?X*_!WQ%XIN614T:S>9=W1
MGQ\H_$X%:4:4JLXTX*[DTEZLRK5H4J<JM1V44V_1'R3_`,%6?^"BTWP1A;X=
M^#;I$\37\?\`Q,;Q#EM.B(^ZOHY]>PK\Y=`OY]4NGN;J:6XN9VWR2R,6=R3U
M)/6N2\<>/]1^*?Q"U+Q%JT\EQJ&L7+7,KN<D%CD+]`./PKJ/"/\`JTK^H<BX
M>H91@HT*:O-ZREU;_P`ET1_*F>\25\YQTL14?N+2,>B7^;ZL^B?V-O$^L:!\
M;-!CTF34'-Q=+YMM:OM-P`.A['C/6OK/QGHOC+XP?#*TM_"VF:E%!%K%\UTW
MVE(TF5I'&SKS@_RKYT_8GTU?!^B>+OB!<@"/P]8_9K0$?,]S-PNWW`#5[K\/
M[G3#^SO\/KOQ-JE]I]C%=WMS.L#%)+R0;B(_Q-?%\03OC%6I13<6H[-W?+*6
MR:O96MZGTG#\+8"5"M)J,U*5N91M'GA%/F:=KM-O39>9YKX^^#_B3X8>4=<T
MN>R2?[CG#(WMN'&:R/#7B>_\(:Q!J&FW4MI=V[!D=&P?Q]17OL/QEN/CUX%\
M:V5W:QP:)I.GK)I]J?F:`J>&+?WCWKYS4Y4'UKNRW$UL1"=+&02E'1I:K57_
M`%U6OJ?.9Q@\/A:M.ME\VX2NXMZ---I[6ZJZ=D_)'WU^R_\`M#0?'#PJ4N"D
M.MV"A;J,<"3_`&P/0_SKK/BU\.[?XF^#I]/N+_5=-"9ECGT^Y,$JL`<<CJ/:
MO@_]GSXF7'PL^*>EZA%(4MY)5@N1V:-C@_EFOT-N)UNM'DE0@I+"64^Q7-?E
MO$N5?V9CHU,/I&6L?)]4?N/!>??VSELJ6+]Z</=EYKH_GU\T?!G_``3ITC6_
MC=\8_&MOXC\9>*[RT\&S+]EA6^*+,?-9`7XY&%Z5[+^V-XAU+XD>.=(\"?#_
M`%?7+/QP"K375A<E+;2X,Y9YP`06*YP#ZBOCKX$?M07O[,NL?%RYTVRGFO\`
M6KU;6.Z";HK$?:),R-[X/`[FOO[]C#POX7T_X2V^M>']4;Q!=Z__`*5J.JRC
M]_<S'EE8<E0IX"YXQ7U/%-&>!QKS.<;Q2BJ<;+EYG!-N5E:UV]'K)^29\AP5
M7I9CERR>G.TVY2JR;?-RJ<E%1N[WLE[RTBO-HV_@7\"KCX36`FU/Q3XB\4:Q
M/$J7%QJ%UOCX_N)C"\DUF?MI^.KSP+^SUK3:7-+%K.J;=/L/*.)#+*<#;[]:
M]6KP3XLZW9_$+]KKPKX:NKVTATOPC;/K-\DLJH&F8;(E.3V)S7PN75)XG'?6
M:_O<EYO32T=4K+35V7S/TG-J5/!Y:\)AO=<[0CKJG+1N[=[I7DWY'`_\$E/C
M1>>,?AEK?A36;F:;5_#MZ[_OR3*RN<G.>>#Q7UI?V:ZC92V[M(B3*4+(VU@#
MW![&O@#2-9M?V4?^"G,IM+RVE\/>-G7S&AD5D7SNBC!QD/C\Z_03IZ&O2XQP
MT8XV.-HJT*\5->3>Z^3_`#/(X`Q<YY=++\0[U,/*5-^:7POYQ_(_.;]KGQQX
MC_8W_:KT0Z-XK\17WA\&*\FLKN[,X$>X!T8D=#DXK]!?!/BVT\>>$--UJPE2
M:SU.W6XB=3D$$?T.17R_^T7\#+/]HWXR_$[0_*_XFEKX;MWM'QDB56210/3.
M,'ZUD?\`!)?XZ7%_X;UCX<:U*5U/PU*S6B.?F,><,H]E(_6O8SG"PQV34\5!
M?O:"CSZ)-QFDU+3>STOZG@\/XRIEF?U<'5?[C$2G[/5M1G!M.*OM=:V]$?6O
MCSQC:?#_`,&:GK=](L=KIENT[D^PX'YU^?O['7CWQ+^UM^UGKL7B+Q+XDL=*
M7SKU-/M+LP+'\WRITR`..*^H/VG[J;XP_$SPQ\+;!V-M>2C5->9>D5K&?E0G
MU=LC'M7AW[)UC9>&_P#@IS\0K.V2.VA*SK%&.`3N'0?05'#U"GA\KQ51K][*
MFY)_RQ327HWJ_1+N:<58FKBLYP5)2M0C54)*[2E)Q<G>VZBK*W=M=#[FM;<6
M=K%"K.RQ*$!8Y8X&,D]S7Q-_P5I^)WB#3IM$TOP_=7\-OHFS5=5-LY554N$C
M#X_VNE?;4T\=K"\LK!(HE+NWH`,D_E7RWX!TK1?VCO"/Q9UG5-0T[/BV:73M
M/\ZX1=D$!(1@"<\LH->)PK5AA\5_:%:/-&FUIYR=OP7,_D?1<:4:F+P7]EX>
M?+.JFT[VLH*_XRY8_,]S_9Y^)T'QA^"OAOQ#`Z.=0L8S*%.=D@&&4^^1^M4O
MVDOAY%X[^&U](=4UG2;G2[>6>WFT^Z,#;]O\6/O#CI7S/_P2'^*$MC:^*OAQ
M?S!I]#NI+BT&[<"F[#X/IG%?7/Q5_P"2:Z[_`->,O_H)J,VP$LLSF5&F[)23
MB_[KU7X.QID>90SC((XBJKMP:DO[T='^*N?%O_!-?PIJ/[3/@CQ/J'B?QAXT
M>^TF^2WM9+75&A"`H3D@#DY%>E_%OX5_&+]GK3I_$W@CQMJ/C&QL`9KG2-81
M9I&C'+;&&">*X_\`X(J?\DR\<?\`85B_]`:OM;:K_*RAE;@@]".XKVN)\VJ8
M3.Z])1C*FFO<<4U;E5TM-/56/GN#,DI8_AS#UI3E&K)/WXRDI7YFDWK9^C35
MCR']D#]KG2?VK?!,UW;PC3M:TUA'?V#-EHC_`'AWVDUZEXBUN'PUX?OM1N6"
MV]A;O<2'T55)/\J_/_\`9S63X._\%3M?T'32$T_5&G\Z).%((WJ/P)-?4?[<
M'CP:)\.+#PU!-'%?>,]0ATQ2T@39$6#2L2>VQ6'XUPYUD-*GFE*CA=*=91FE
M_+%ZO[K/Y'I</\3UZF35L1C;.K0E*#>RE*.B?_;UTO4^8_V&/C_K]E^VMKFG
M^)KR_EA\:[FLA<.2"H9C#M!XQM/;TK]!:^!/^"E'AFP^$?B+X=>/?#%[8/=Z
M`(K&4V\REE6+!0X4]\M7V_\`#3QM;_$?X?Z/KUK@0:M:1W*C.=NY0<?6MN+J
M=/$4L/FM"'+&I'E:[2AI^*L<_`E:KA:V*R3$SYYTI<Z>]XSU_"5_O-RBBBOB
M#]&.THHHH`YCQ#_R&)O^`_\`H(KX^_X+2>*9?#W[%-[:QLZKK%]':R;3@$`%
MN?;(K[!\0_\`(8F_X#_Z"*^/_P#@M%X3G\2_L5WMS"&*Z-?1W4F!GY2"O]:^
M@X4Y/[8PW/MSQ_/3\3YSB[G_`+%Q7)OR2_+7\#\;[+_CY3ZUZ!X2.(TKS^R_
MX^4^M>Z_LE?#)_B_\8O#N@*H:&\ND-SGHL*D&0_@H-?U%F%:-*C*K/:*;?R/
MY3RRA.M65*FKN327JS[V^&G@KP_^S]^P_H&M>)=.EU.9[Q=3;3PO^LG=2(O.
M_P!@`-UXYJ*]\1>%_&?[.?@W4_%L=]:)?ZG=S01Z>HVQ$LQ*X/8#@5S_`,,?
MBY;_`!]^+OQ*\$R2%M(URR\C28SSM>VXC5?0G+=*S?&VGS:5^R9\.[:X0QSV
M^I7D4BGLRE@1^8K\?IX6;Q"6(;52512NGM&4)-)=K.Z?H?JN-QL%A92PT4Z4
M*;C9J]Y0J03;[W337:YW.N7WAW1?V=-7N?`L-TJWMXMIJLUTQ,RQXRN/0&O"
M:]._9MN$\07&N>$9V!A\26C+"#_SW0$H?T`KS:]LY-.O)K>8%98',;CT(.#7
MN9;35&K5H-MNZE=ZMIK2[\FFOD?&9Q6>(H4,3%)1LXV2LDXN[LO--/U;(U;8
MP;IM.:_1WX2:NVO_``5T6]9B[7&G!B?P(_I7YQ*N]E7&=QQ7Z`Z-\--1UWX`
M:!H5EK%UX?FCM$62:!`SE2#E>>G6OF..XTW3H*;M[SU[*VNVO8^V\+9U8UL3
M*$>;W%IW=]-].Y\B?\$WOAII'Q=\9_'3P_KEI'>:??NJ.K#)4_:),,I[$'N*
MR]`UGQ5_P2O^//\`9NI&YU3X>:]*6C9260(3]X?W9%[COBOHWX(_\$^8/@#X
MRN-:\/\`C+6HI[]@;U'162[&<X;\2:]:^./P+T#]H'P!=>'_`!!;":WG7]W*
MN!)`_9U/;FN/&\581YA43?M<+645*-FFFHJ/,K]5:ZMT/8R[@K'1RNDXKV.,
MH.3A*Z:DI2<N65MXN]FGL_(V="^(.D>(_`T?B2RO(+G2)+<W0G1P5V`9//J*
M^</V=?V??#'[4$'B+XC>+=-75Y/$NIRG3FD=AY=K&Q1`,>H`-:/AK_@G4W@_
MP+>^&=-^(?B>UT+4`5FM%*E"#U`],^U>A_LZ?LV7/[.^E6^E6GBC4=3T.T5E
MALKB-=L6?0CWKP/;8/!4*WU#$/GDU9VE%\BNVK]V[>6A]/[#'YAB</\`VGA%
M[."?,N:,ESNR3MU25[=;O;0^:?\`@I%^R'X?^$OPCL/&/@K2UTJ]T&]22X>,
MDX7(VMSW#8KZL_9=^*T7QK^`_ASQ#$P>2[M52;G)$BC#9]#D9_&JO[2'[/S_
M`+17A4Z'/KU[I.DSILNH($#?:?FR,D],8KAOA)^PW>?`_P`/7&D^'/B!X@LM
M.N,MY.U2L;G^)<]#6]?,L/CLHIX?&5OWT)-IM2?NO=-V?75'/ALHQ66Y[5Q.
M`P_^SU()22<5[\=FE=:6T>VI>^%5_'JG[<?Q+,<D+K:Z9:0%0V6)VH3QZ`\5
M\O\`[8?AZ[_8=_;-T;XDZ+$RZ/KDOVB:).%9A@2QD=,$8('K7T9\._V"YOAE
M\1+WQ3IWCW7VU?4_^/V655?[4,YPP^M>@_M'_LVZ1^TO\/K;0=:D9!:SQW$=
MPJ@N&4C(^C#(_&NK!YU@\'F$)*?M*$X*G-6:T44GH_-71Q9AP_F&895.+I^R
MQ$*DJM-\R>KDY)77D[.^ESF?V,-"O/$NE:U\1]9A9-7\=7/GPH_W[:S7_51^
MW'/'K7SS^SXX'_!5OQD"0"TMR`.YX-?9_B#P%+-\/X=!T/4I]`%JD<,%Q`H9
MXD08V@'U&*\"T+_@FC:^&_B8_C&S\<^(8O$<DS3O>84N[-G<3]036669OA']
M<GB*G)[6#A%6;LM.7;HDDNYMG&1XY?4*>%I>T]A-5)RYDN9Z\UK]6VWV/1_V
MU_B=+\,?@%J;V<C)JNM,NEV.W[QEE.W/X`U@?#W_`()[_#G0O`^D6FJ>'8+O
M4K>UC2ZF:1LRRA1N;@]SFJWQ7_8<O/C1>:?-KWC_`%ZX72I!-:QHBJD<@(._
M'<\5[+\/O#&H>$M!6TU+6;C7+A3_`,?,R!7(]#BO-GCH83`PI8&N^=R;G;FC
M?91UTNDK_-GKT\NGCLRJ5\RPR]FHJ,.;EE;5N3M=V;=ODCX0^(WAVR_8*_X*
M$^&]3TF!K+PKXB6.-H@25(D^1U^@8@_A7W5\4)%G^&&MR1L'1["1E8<@@H>:
M\<_:,_8%L_VFO%T>J:_XIU4)9LQLK>)%"VBDYV@]^>]=')^S%K3_``O3PL?'
M^N-:@-&T[(IE:(J%$>?08/YUZ&:8_!8ZGA*TZW[Z"49MJ6J3NG>VK2T9Y62Y
M9F&6U<;0IT/W%23E32E'1M6:M?1-ZKLCPG_@BHP/PT\<*"-W]JQ''?&QN:^N
M/B;\4-%^#O@Z]U_7KV&RL;",R,78!I"!PJCJ23Q@5X%\+/\`@FY'\%+J>;PM
MX_\`$FCM=?ZX0[=LOU!KL(?V&_#WB+48+WQGK/B+QM<6YW+%J-T/LV<Y_P!6
MH'\ZG/J^5XW,ZF.=9N$FGRJ+YM$E;6RZ;W^1?#&&SG+LFI9:L.E4@FN9S7+J
MV[Z7D[7VMKW/!?\`@GI\*]6^,/[1WB3XRZK:36VF7$LJ:7YRD--O/4`]0%QS
M7J'B[P5I'[6/[7]_I6L0+J7AOP!I_EO&&(1KR0@D''=1FO=O$/@;[3X'?1-#
MNCX=55"0RVL8!@4=E%>2_!O]B:X^"/BR_P!7TGQQK4LVKW`N-06X17%VP.23
M[D<5=7/J6)K5<;*?LYJ*A3BDWRK1;I;VNK]WT(H\-5L'AZ&71I^VIN;J5I-Q
M7-)W=N5O5<UG;LNK,GX_?\$]?`>N?!WQ!!X?T""RUH6;R6<P=B4=1D=3[5SO
M_!)+XR2>,O@K>^%+Z1SJ/A6XV(KGYS"W]`>*^F/B!X8O/&'AB>PL=5GT:>?C
M[3"H9U&.0`?6O`_A7_P3DM_@UXVFU_0?&VO6=]=G-UM5=MR-V2K#TS6>%S>E
MB<JK8/,:S<G)2@WS2::WN]=&C3&9%7P>=X?'Y3ATH*,HU$G&*:>UEI=IZ^A]
M+44D:E(D5F+,H`)]3CK2U\8?H*.THHHH`YCQ#_R&)O\`@/\`Z"*XCXW_``OM
M?C3\)=?\+7H4P:S:/`"W17(^5OP.#7;^(?\`D,3?\!_]!%4JTI594YJI!V::
M:]49UJ4*L)4ZBNI)I^C/YVOB'\.-1^$7Q)U3PUJT,D%_H]T]M('&"P5L!OH1
M@_C7TO\`L92#X7_!_P`>?$"0,EQ;VG]BZ8PX83SKM9E/LC9KZ\_X*B?\$XF_
M:(MCXY\(0I'XMTV/_2K51@:G&!V_VQV]:^-?@@WAK4/!4G@GXA>*O$7A"/2K
MUIQ9Q:<KIYF,$OD;MW;GM7]%4.(:.=97&<7[R<?:12;:UN[))MIV^YG\U5^&
MZ^29M*G->ZU+V<FTD[JRNVTDXWV[H7X">.[CX>?$_1=>BD*S6-TLKOG!()^;
M]":^W/V\;#3K'X7>`GTI0MC?7,]['C'_`"V7S#^K5\XZ)\)O@=&RF+XHZY(?
M?2@/Z5ZM<2?#WQ?X;TK2;WXIZY?6&CY%I')IP_=9&/3TKR,UJ4ZV-H8R$9KD
MO=<D]59VZ=&W][-LMIU:&78G`U)4W[2W*_:4]&FF_M=4E]R/._"?B2;P?XFL
M-4MR1-83I.H'&=I!Q^.*[#]I30X;#XBMJ5HJBQU^!=0AVC"C>/F'YYK3/P]^
M%8!/_">:J?\`MP'^%97B+3&^(NO:1X<\+WNI^(8+)#%;M/`$,8)YQC^'ZU:Q
M,*F(C6BG%)-2<HN*MONTEHU^+/)>#JTL)/#3<9.4HN*C*,GS;/1-O5/[TAO[
M-_PKG^+'Q4TZQ6,M9V\@N+IB/E$:G)'XXQ7W;\1_B-I7P:\%2:SJPO!IEELC
M<VT!F=0<*/E':N7_`&:O@':_`SP>(7*3ZO>X>[GQGG^X/8?TJ#]LH27?[/&N
MVEO;WMW<W@2..*UB:20G<"2`H)&!WK\WSK,Z>:YI3I+^$FHKI=-ZO^NB/V7A
MG)*N1Y+5KR5JTHN3ZV:7NQ\_/S9T7B;XX:'X1_X1X7J:HI\42+%8".T9RS%=
MP#<_+QZUL^&/%T7B:SN)S;7>GK;W,EMMNT\HN4;&Y<GE3U!KYX\>_#^'PQJO
MPJU*WN_&6I1Q7:2W*7$D]REJ@CP6*;?D(/K7$^*?$6NBRM=*WZ_<M<ZQK12.
MY2?<D#M(;>;`&\A05*G&!@5E2R"C6A'V,M7>[?DY=/1+KU.NKQ/B,/4G[>":
M5K)>:AN_63V6R/J:V^+ME<?%VY\'F"1+JVLDOC.S`1,K$@`>_!J[\0_B=I/P
MRL+:;4WG:2^F%O:V]O&99[F0_P`*J.OOZ5\AVFAV_BK4+C5-.N?%6I06?AJ)
M(;](IU>:Y25MRYVY)![5['\7?#^NWL_PO\<6EG>:LGAD[]2LPA$P26'8TH4\
MEE/..M3B,DP].M3@Y63333T]Y1NEKMS/378O"\18JKAZLU"[3336MHN5F[+?
ME5WIN>C>"/CCI'C+Q1<Z$\5]I.N6L8F-E?0F%Y(ST=,\,/7'2NR\U22`RY')
MY'%?+_Q!UZU_:?\`BG?ZIX2EN4F\$Z#>P3/AK:\>ZDC8QQA&P^`V.2,9K#'B
M_P`3-K=]?0Z;XNDM;CPYI]O+&R2Q[[E6<3,.,CMG')J9</JHDX/DE9-Q>Z;>
MW3=:HJ'%,J;:G'VD>9J,X[226KLK[/W7;1[KL?2_B;XG6OAGQOX=T22WFF?Q
M(TR03QD&-#%$TA!]R%-:/AOQ?;>(]-M[@)-9/<!BL%THBFPK8)VD]/\`&OD_
MX9:MK.FWGA)-:T[Q&(])UW5I"XM9G-O;303+"58KG&64#N*U?A?X+O-=UOX?
MS^(4\5`3Z?J-C<R@S(T,IG!B+\<?*<Y/'%7B.'Z5.-G/9/5:W:YWHK]HK[UW
M,\+Q16JSO&%^9JR>ED_9K5V[RETZ/L?5LMRD43/N#!`6PO).*\OLOVPO!VI,
MRPG6$=IKFTA:XL6ABGN(`Q>%7)QN^4X'>N?_`&5=#UV!]=N]<O9[NVT1Y=+L
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MA&I2O.ROKHW9>5E?KV>FI]I^?&2`)(\GI\PH\^/86\Q-HX)W#`_&OCGXJ^#-
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MUF-<62E&,H4&^:^E[-65[.ZW=[JU[J[/K^XOH+2)Y)9HHD099F<`+5#3_%<.
MH^([W3DAN5-C&DK7#)B"0.,@*W<COZ5\D:C;:WXXTWQ%]HMO%DEJ^DZ>0ACF
MC:2:-CYNT8SGU]:V-=NO$/A_Q!XA7PW9^)[C0!::9(8'27S3`H43K&6'WL]0
M.2,U:X<BKQ=1<WW)?#UOO[ST\C-\62=IJD^7[V_CZ6V]U:^:T/K'[1'L#>9'
MM8X#;A@_C7.^$/B3;^+/$OB73!;RVDOAFYBMIGE("RF1"X8>V!7S%\=;G4I_
M!YM/!VB^-((;N%KJU:=YCLEW#[J@<$8/#8%7O%VIZOK1\8SVBZY87&HWUA>*
M[:=,T=PL=N5=7`7)&[CCFBEP[%T^:4_BV[JTHK5)O=-Z>05N*I*KRQA\._:5
MXS=DVELU'7S/K-6#J"I#`]".0:*Y'X`W-Y>?!/PQ+J%G/I][)8J9K:9F:2%M
MS<$MSTP>><&NNKYJO2]G4E3O>S:^YV/K\-6]K2A5M;F2?WJYVE%%%9&QSNNV
M4\VJRLD,KJ<8(0D'Y15-M-NN,6\__?LUUU%`'*6>G2K.#+:W#)_US/6O!OVI
M_P!@'P[^T1<27\FDK9ZP1A;VVC\N0^FX8YKZDHKJP>-KX6HJN'FXR75')C,#
MA\73='$P4HOHT?E?K_\`P2B^(OA>\)TJ.+5;=3P65HFQ].<U=T#]@/XH6959
M/#\BGU^;'\J_4.BOK(\?YIR<LW&7FUK^#2/AZWACDTYN45*-^BEI^*;_`!/@
M+P=_P3W\67]PC:O$]I$#\RQH68_CVKZ=^!_P#L?@[I9AMM,5'D`\R0Q%Y9/J
M<5[!17A9CG^.QJY:\_=[+1?\'YGT&3\*99EKY\+3][^9ZO[WM\K''S:?<&5B
MEI<!">`4/^%-&GW8.1;7`/\`US/^%=E17C'T9QO]GW8SBVN.?^F9_P`*PO%?
MPDT[QMJ-M>:GI,]Q=6:,D,HWHZ*W49&.#FO3Z*NG4E"7-!V?D9U:4*D>6HDU
MV>IP.@^$%\+Z1!8:?ITMK:6XQ'&D;86KG]G777[-<9_ZYG_"NRHJ92;=WJRH
MQ44HQ5DCRH_!/1O^%@IXJ703'X@1/+^UHCHSKC&&`X;\:Z/^S[O_`)]KC_OA
MO\*[*BKJ59SMSMNRLK]%V]"*5&G3O[.*5W=V5KON_/S..^P79ZVUS_WPW^%1
M7FBW%]9S026USY<Z&-\(P.",'FNVHJ$^IHU?1GG?A/P%#X'T"WTS3-.FMK*V
M!V($8XSR3D]236E_9]V>MM<'_@!_PKLJ*<YRDW*3NV*$(PBH05DM$CC?[/N_
M^?:X_P"^&_PH_L^[_P"?:X_[X;_"NRHJ;%W.-_L^[_Y]KC_OAO\`"C^S[O\`
MY]KC_OAO\*[*B@+G&_V?=_\`/M<?]\'_``H_L^[_`.?:X_[X/^%=E10(XW^S
M[O\`Y]KC_OAO\*/[/N_^?:X_[X;_``KLJ*!W.-_L^[_Y]KC_`+X;_"C[!=_\
L^UQ_WPW^%=E1185SD5TZY*C-O.#_`+AI?[-N?^?>?_O@UUM%`!1110!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
